A twin study of heritability of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity

Atherosclerosis

Volumn 205, Issue 1, 2009, Pages 181-185

  Lenzini, Livia ^a   Antezza, Katia ^a   Caroccia, Brasilina ^a   Wolfert, Robert L ^d   Szczech, Radoslaw ^b   Cesari, Maurizio ^a   Narkiewicz, Krzysztof ^b   Williams, Christopher J ^c   Rossi, Gian Paolo ^a,e  

^a UNIVERSITY OF PADOVA   (Italy)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c UNIVERSITY OF IDAHO   (United States)

^d diaDexus San Francisco ^*  (United States)

^e UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Heritability; Human; Lp PLA2; Twins

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE;

ADOLESCENT; ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIZYGOTIC TWINS; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENETIC VARIABILITY; HERITABILITY; HUMAN; MALE; MONOZYGOTIC TWINS; NORMAL HUMAN; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; DISEASES IN TWINS; ENVIRONMENT; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; LIKELIHOOD FUNCTIONS; LIPOPROTEINS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC;

EID: 67349203563     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.08.045     Document Type: Article

References (30)

1. Stafforini D.M., Tjoelker L.W., McCormick S.P., et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 274 (1999) 7018-7024
2. Macphee C.H., Nelson J., and Zalewski A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol 6 (2006) 154-161
3. Kiechl S., Willeit J., Mayr M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 27 (2007) 1788-1795
4. Blencowe C., Hermetter A., Kostner G.M., et al. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 270 (1995) 31151-31157
5. Stafforini D.M., Prescott S.M., and McIntyre T.M. Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem 262 (1987) 4223-4230
6. Stafforini D.M., McIntyre T.M., Carter M.E., et al. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 262 (1987) 4215-4222
7. Zalewski A., and Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25 (2005) 923-931
8. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
9. Blake G.J., Dada N., Fox J.C., et al. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol 38 (2001) 1302-1306
10. Ballantyne C.M., Hoogeveen R.C., Bang H., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109 (2004) 837-842
11. Koenig W., Khuseyinova N., Lowel H., et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908
12. Oei H.H., van dM I., Hofman A., et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation 111 (2005) 570-575
13. Winkler K., Hoffmann M.M., Winkelmann B.R., et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Clin Chem 53 (2007) 1440-1447
14. Sabatine M.S., Morrow D.A., O'Donoghue M., et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 27 (2007) 2463-2469
15. Kolodgie F.D., Burke A.P., Skorija K.S., et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26 (2006) 2523-2529
16. Guerra R., Zhao B., Mooser V., et al. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins. J Lipid Res 38 (1997) 2281-2288
17. Stafforini D.M., Satoh K., Atkinson D.L., et al. Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 97 (1996) 2784-2791
18. Hiramoto M., Yoshida H., Imaizumi T., et al. A mutation in plasma platelet-activating factor acetylhydrolase (Val279 → Phe) is a genetic risk factor for stroke. Stroke 28 (1997) 2417-2420
19. Yamada Y., Ichihara S., Fujimura T., et al. Identification of the G994 → T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 47 (1998) 177-181
20. Unno N., Nakamura T., Mitsuoka H., et al. Association of a G994 → T missense mutation in the plasma platelet-activating factor acetylhydrolase gene with risk of abdominal aortic aneurysm in Japanese. Ann Surg 235 (2002) 297-302
21. Ninio E., Tregouet D., Carrier J.L., et al. Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease. Hum Mol Genet 13 (2004) 1341-1351
22. Kruse S., Mao X.Q., Heinzmann A., et al. The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma. Am J Hum Genet 66 (2000) 1522-1530
23. Abuzeid A.M., Hawe E., Humphries S.E., et al. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 168 (2003) 283-288
24. Cesari M., Narkiewicz K., De Toni R., et al. Heritability of plasma adiponectin levels and body mass index in twins. J Clin Endocrinol Metab 92 (2007) 3082-3088
25. Rossi G.P., Narkiewicz K., Cesari M., et al. Genetic determinants of plasma ACE and renin activity in young normotensive twins. J Hypertens 17 (1999) 647-655
26. Cesari M., and Rossi G.P. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. Arterioscler Thromb Vasc Biol 19 (1999) 1378-1386
27. Caslake M.J., Packard C.J., Suckling K.E., et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis 150 (2000) 413-419
28. Williams C.J., Christian J.C., and Norton Jr. J.A. TWINAN90: a FORTRAN program for conducting ANOVA-based and likelihood-based analyses of twin data. Comput Methods Programs Biomed 38 (1992) 167-176
29. Christian J.C., Norton Jr. J.A., Sorbel J., et al. Comparison of analysis of variance and maximum likelihood based path analysis of twin data: partitioning genetic and environmental sources of covariance. Genet Epidemiol 12 (1995) 27-35
30. Rossi G.P., Maiolino G., Zanchetta M., et al. The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients. J Am Coll Cardiol 48 (2006) 1166-1174